ArticleFrontiers in immunology2026
Stereotactic body radiotherapy plus lenvatinib and sintilimab with and without transarterial embolization for advanced hepatocellular carcinoma with portal vein tumor thrombus: a dual-center, propensity score-matched retrospective analysis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Transcatheter arterial chemoembolization combined with stereotactic body radiation therapy versus transcatheter arterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Novel Strategies for the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Review.Journal of gastrointestinal cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Portal vein tumor thrombus (PVTT) in hepatocellular carcinoma (HCC) is associated with poor prognosis and limited efficacy of current first-line therapies. Combining locoregional and systemic therapies may enhance antitumor immunity. However, the safety and efficacy of dual locoregional therapy (LRT) with stereotactic body radiotherapy (SBRT) and transarterial embolization (TAE) along with targeted immunotherapy is unclear. Methods: In this retrospective real-world study, we analyzed 204 patients with Barcelona Clinic Liver Cancer stage C HCC and PVTT treated with SBRT plus lenvatinib and sintilimab, with or without TAE, between June 2018 and December 2022. Propensity score matching (PSM) was performed to balance baseline characteristics. The primary endpoints were progression-free survival (PFS) and overall survival (OS), and the secondary endpoints included local control (LC) and safety. Results: After PSM (64 patients per group), the TAE group showed significantly longer median PFS (11.0 vs. 6.0 months; HR = 0.71, p=0.044) and a trend toward improved LC than the non-TAE group (51.0 vs. 36.0 months; HR = 0.54, p=0.066), but comparable OS (19.0 vs. 18.0 months; p=0.606). Multivariate analysis confirmed TAE as an independent predictor of reduced risk of progression (HR = 0.52, 95% CI: 0.36-0.76). Objective response rates (40.6% vs. 39.1%, p=0.861) and grade ≥3 treatment-related adverse events (50.0% vs. 50.0%, p=0.854) were similar between groups. TAE did not increase hematologic or hepatic toxicity, supporting its tolerability. Discussion: Adding TAE to SBRT, lenvatinib, and sintilimab prolonged the median PFS in patients with advanced HCC and PVTT, showing comparable safety. This real-world study supports dual LRT combined with targeted immunotherapy as a feasible treatment option and merits prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.